New study tests Nerve-Saving support for bladder cancer patients

NCT ID NCT07629700

Not yet recruiting Symptom relief Sponsor: University of Florence Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a supportive product called Neuridase can help reduce nerve damage (peripheral neuropathy) caused by a combination of two cancer drugs (enfortumab vedotin and pembrolizumab) in people with advanced bladder cancer. About 40 participants will receive standard treatment plus Neuridase, and researchers will track nerve symptoms and quality of life over time. The goal is to understand how neuropathy develops and whether Neuridase can improve treatment tolerability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Neuridase (a supportive non-drug product)
What this could lead to: If it works, this could point toward a way to manage nerve damage from cancer treatment, helping patients stay on therapy with better quality of life.
What could go wrong: This is a small, early exploratory study with no control group. Neuridase's role is unproven, and the main focus is observation, not a guaranteed benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

peripheral nervous system disorder transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL NERVE DISEASE UROTHELIAL CARCINOMA (UC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.